Brief: Theravance Biopharma, Inc. Announces Strategic Actions And Reports Fourth Quarter / Full Year 2022 Financial Results And Business Update

Theravance Biopharma

27/02/2023 22:04

Feb 27 (Reuters) - Theravance Biopharma Inc  TBPH.O :
    * THERAVANCE BIOPHARMA, INC. ANNOUNCES STRATEGIC ACTIONS AND
REPORTS FOURTH QUARTER / FULL YEAR 2022 FINANCIAL RESULTS AND
BUSINESS UPDATE
    * THERAVANCE BIOPHARMA INC - DISCONTINUING INVESTMENTS IN
RESEARCH, REDUCING HEADCOUNT BY APPROXIMATELY 17%
    * THERAVANCE BIOPHARMA INC - INCREASES CAPITAL RETURN
PROGRAM TO
$325 MILLION FROM $250 MILLION
    * THERAVANCE BIOPHARMA INC - APPOINTS SUSANNAH GRAY TO BOARD
AS
NEW INDEPENDENT DIRECTOR
    * THERAVANCE BIOPHARMA INC - ON TRACK TO BEGIN ENROLLMENT IN
AMPRELOXETINE PHASE 3 STUDY IN Q1 2023
    * THERAVANCE BIOPHARMA INC - DISCONTINUING INVESTMENTS IN
RESEARCH
    * THERAVANCE BIOPHARMA INC - REAFFIRMS ITS EXPECTATION THAT
IT
WILL GENERATE NON-GAAP PROFIT IN 2H 2023
    * THERAVANCE BIOPHARMA INC - TOTAL REVENUE FOR Q4 OF 2022
WAS
$14.6 MILLION

Source text for Eikon:  ID:nPnbdDXDna 
Further company coverage:  TBPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))